Skip to content

Clinical trials

Glomerulonephritis, IGA trials in France

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Glomerulonephritis, IGA Country / region: France Clear all

30 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20081
20111
20121
20131
20161
20184
20192
20202
20213
20223
20233
20242
20255
20261

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed11
Recruiting8
Active, not recruiting6
Terminated3
Enrolling by invitation1
Unknown status1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Novartis Pharmaceuticals6
Centre Hospitalier Universitaire de Saint Etienne4
Assistance Publique - Hôpitaux de Paris3
University Hospital, Limoges3
Alexion Pharmaceuticals, Inc.2
Calliditas Therapeutics AB2
Otsuka Pharmaceutical Development & Commercialization, Inc.2
Alnylam Pharmaceuticals1
Alpine Immune Sciences Inc, A Subsidiary of Vertex1
BioCryst Pharmaceuticals1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Glomerulonephritis, IGA30
Glomerulonephritis6
Renal Insufficiency, Chronic6
Kidney Diseases5
Proteinuria3
Urologic Diseases3
Glomerulonephritis, Membranous2
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis1
Diabetic Nephropathies1
Glomerulonephritis, Membranoproliferative1

Trials

Showing 1 to 25 of 30. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.